The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | WM: BTK inhibitors
From the International Myeloma Workshop (IMW) 2019, held in Boston, MA, Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the exciting new agents for the treatment of Waldenström’s Macroglobulinemia (WM) that are emerging from current clinical trials. This discussion highlights venetoclax, ibrutinib and newer BTK (Bruton tyrosine kinase) inhibitors such as acalabrutinib and zanubrutinib.
